tradmap

MBOT Financials Microbot Medical Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has declined 56.0% per year over the past 5 years.

Financial health

  • The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
-$33M -$16M $1M $0 2012 2014 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-16305% -7761% 783% 0% 2012 2014 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$28M -$14M $0 2012 2014 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $14M $29M 2012 2014 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$72M $7M $86M $0 2012 2014 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$13M -$13M $4M
2024 -$11M -$9M $3M
2023 -$11M -$9M $2M
2022 -$13M -$12M $2M
2021 -$11M -$9M $13M
2020 -$9M -$7M $20M
2019 -$7M -$7M $29M
2018 -$7M -$6M $5M
2017 -$8M -$5M $11M
2016 -$10M -$811000 $3M
2015 $116887 -$921000 0.0% 782.8% -$767000 $437000
2014 -$1M -$27M $791000
2014 $1M -$33M 0.0% -3053.2%
2013 $172297 -$26M 514.6% -16304.8% -$28M $358536
2012 $1M -$28M 80.8% -1601.5% -$20M $331250 $8M

Frequently asked questions

Is MBOT growing its revenue and profit?

Over the past 5 years, Microbot Medical Inc.'s revenue has declined 56.0% per year. These are computed facts, not advice.

How much debt does MBOT have?

As of FY2025, Microbot Medical Inc. reported — of total debt against $4M of cash.

What is MBOT's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.